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Abstract
Background:  Newly diagnosed insulin-dependent diabetes mellitus is characterised by a
temporary recovery of endogeneous insulin ("remission") after the beginning of medical treatment
with subcutaneous insulin injections. Although most diabetologists think, that insulin reserve is
related to reduced occurrence of diabetic long-term complications, such as eye, nerve and kidney
disease, there is only one prospective controlled clinical study (the DCCT) addressing this
question, however as secondary hypothesis.
Methods/Design: Therefore, we composed a trial consisting of two cohorts with two therapeutic
options within each cohort (conventional versus intensive therapy) and a three-year follow-up. In
one group the patients are randomly assigned to the treatment regimes to test the statistical
alternative hypothesis if variable insulin dosage is superior to fixed insulin injection in preserving
insulin reserve measured by C-peptide in serum. Another group includes patients who prefer one
of the two therapies, decline randomisation, but consent to follow-up. Apart from the
determination of insulin reserve as a biological parameter a second primary endpoint was defined
as 'therapeutic failure' according to the criteria of the European Association for the Study of
Diabetes. Patients pass a training program to help them self-manage diabetes. A standardised
protocol is being set up to minimize centre effects and bias of health care providers. Potential
patient dependent bias will be investigated by questionnaires measuring psychic coping processes
of people with diabetes. Management of visit dates is directly navigated by the database. Automated
visit-reminders are mailed to patients and caregivers to optimise the number of visits on schedule.
Data quality is regularly monitored and centres are informed on the results of continuous data
management.
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Background
Complications of diabetes
The incidence and the risk of type-1 diabetes differs
between populations with highest rates reported for Fin-
land (> 30 cases per year and 100,000 inhabitants), and
minimal rates for developing countries (< 2). The inci-
dence rates in central Europe vary between 5.2 and 12.1.
A census from the early 80's reported 7.4 cases per year
and 100,000 for Germany [1]. It has long been expected
that the level and duration of high blood glucose (hyper-
glycemia) is strongly associated with a variety of microv-
ascular complications, such as eye, kidney, and nerve
disease.
The Diabetes Control and Complications Trial (DCCT), a
randomised trial included a total of 1,441 patients with
type-1 diabetes and was published in 1993. The DCCT for
the first time provided unequivocal evidence that, in fact,
lower blood glucose concentrations delay the onset of dia-
betic complications [2]. Subjects chosen for the primary
prevention cohort had had diabetes for 1–5 years with no
evidence of eye disease or initial kidney disease. The bio-
logical parameters used in this study have become impor-
tant for studies on patients with type-1 diabetes, in
general. Glycemic control was assessed with glycosylated
hemoglobin (GHb). GHb is widely used in diabetes stud-
ies to describe the mean blood glucose level over a period
of 4–6 weeks. Eye disease is diagnosed by fundus exami-
nation, and nerve disease is assessed by testing the vibra-
tion threshold of the foot. Measurement of albumine in
the urine is a screening method to detect diabetic kidney
disease at an early stage.
Residual Beta Cell Function
A few months after the initiation of insulin therapy endo-
geneous insulin production recovers. Disease remission is
characterised by a significant reduction of therapeutic
insulin, sometimes patients are even completely "off insu-
lin". Although insulin therapy has been practiced by phy-
sicians for decades, it is hypothesized that only modern
insulin therapy has the potential to maintain a significant
insulin reserve over a longer period of time mainly by
reducing the glucotoxic effect on the pancreatic cells.
Treatment with immunosuppressive drugs to protect insu-
lin producing cells from the immune attack showed that
initial improvement did not last longer compared to insu-
lin injection alone. These studies used plasma C-peptide
concentration for the measurement of insulin reserve
because it is secreted in equimolar amounts with endog-
eneous insulin. The C-peptide radioimmunoassay did not
crossreact with injected insulin circulating in the blood
stream. It was also found that adult-onset patients with
type-1 diabetes have a longer period of residual insulin
secretion than children [3].
Recently, intrinsic biological acitivity of C-peptide was
described after years of general belief, that it is not biolog-
ically active [4].
A subgroup of 303 participants of the DCCT trial who
were diagnosed for diabetes less than five years from base-
line had a positive endogeneous insulin response. These
patients were reported to have a lower value of mean
blood glucose as GHb and also a 50% reduced risk for
progression of eye disease [5].
It was also observed that hypoglycemia (low blood glu-
cose concentration) – a typical side effect of the subcuta-
neous injection of insulin – occurred less frequently in
patients with residual C-Peptide [6].
Conventional and Intensive Insulin Therapy
The majority of patients face a challenge when the goal is
optimal regulation of blood glucose. Indeed, only 5% of
patients in the DCCT, a carefully selected and closely
monitored group, maintained glycosylated hemoglobin
levels in the normal, nondiabetic range through the whole
trial. Optimal diabetes care is a behavioral, psychosocial
and motivational challenge for caregivers and patients.
Therefore, the term "intensive" insulin therapy describes a
comprehensive approach to the goal of optimal glycemia.
In principle, different educational strategies have been
developed to teach patients how to increase the number
of insulin injections and frequency of testing. The "inten-
sive" strategy also includes a systematic approach to quan-
tifying food and matching insulin to food intake, and
education that enables patients to change aspects of the
regimen for varying circumstances. By contrast, "conven-
tional" therapy is a less complex and demanding regimen
concerning the performance of several unpleasant tasks:
injections (not more than three per day), testing, dietary
modifications, and exercise routines.
Hypoglycemia is the principal adverse effect of intensive
diabetes management. Fear of hypoglycemia is an impor-
tant determinant of patients' personal goals for glycemic
control. In the DCCT, intensively managed patients had
three times as many episodes of severe hypoglycemia as
their conventionally treated peers.
In Germany, intensive insulin therapy has become stand-
ard in the past 10 years, 8 out of 10 subjects with long
standing insulin-dependent diabetes practice this kind of
therapy [7]. Most care providers feel, that intensive ther-
apy should be implemented from the first day of diagno-
sis, because they have the impression that quality of life of
the patient is superior compared to conventional therapy.
A pilot trial conducted at our department on 49 adult
type-1 diabetic patients with persisting insulin reserve andBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/5
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randomised for either intensive or conventional therapy
resulted in reduced prevalence of peripheral neuropathy
in the intensively treated group [8].
Rationale
Although C-peptide was measured in some patients of the
DCCT we must express our concerns on the validity of
these data, since insulin reserve was not the main objec-
tive of the DCCT. A bulk of uncontrolled trials in the past
20 years has implicated that residual C-peptide was bene-
ficial for the prevention of diabetes related vascular dis-
ease. This is an important reason for the conduction of
this trial. Further, intensive insulin therapy was thought to
be the optimal way for glucose control in type-1 diabetes,
however only a minority of patients comply with all the
elements necessary for optimal control over a time period
of several years. Therefore we think that our trial will help
to settle the question whether preservation of residual
insulin/C-peptide facilitates stabile glucose levels. Moreo-
ver, intensive insulin therapy is considered optimal for all
patients, however a major obstacle is the increased inci-
dence of severe hypoglycemia. We had observed in the
pilot trial that patients with residual insulin on intensive
therapy had no episode of severe hypoglycemia (defined
as the need of intravenous injection of glucose).
Since 1998 we planned a prospective randomised trial to
document the advantage of intensive insulin therapy in
the preservation of insulin reserve and also the protection
from complications by residual insulin in type-1 diabetes.
This would require a large sample size, which could only
be realized by a multicenter trial. Furthermore, such a
study would have to recognize aspects of self-manage-
ment, life quality, training, psychosocial factors, and cop-
ing strategies of the patient.
To begin with we performed a telephone survey in twenty
clinical diabetes centers in Germany. It became clear that
the access of a sufficient number of patients to such a trial
would require the collaboration of several centres and
years of cooperative data collection.
Aims and objectives
The DCCT landmark study for the treatment of insulin
dependent diabetes demonstrated that reduction of
hyperglycemia was associated with prevention of microv-
ascular complications. But there still remained several
open issues [9].
Will intensive therapy delay the breakdown of patients'
own remaining insulin output in contrast to conventional
therapy?
Will intensive therapy improve glucose control and delay
or prevent the development of long-term complications?
Which factors determine the preservation of C-peptide
concentration when diabetes proceeds with time?
Design
The NeuDia Trial is a national multicenter open control-
led randomised study. Four clinic-based diabetes centres
in Germany participate in the recruitment process. The
protocol was approved by the responsible institutional
review boards. Each recruited subject has to sign an
informed consent form. Patients give their consent to ran-
domisation and/or collection of data depending if they
enter randomisation or the observational follow-up.
Intervention
Interventional cohorts will be instructed to practice basis-
bolus (intensive) insulin therapy. This therapy includes
frequent injections at meal times with variable doses of
short-acting insulins, estimation of carbohydrate content
of the meals, self-dosage of insulins, self-management of
insulin requirement. The participating centres have agreed
on the detailed algorithms of this intervention.
Control (conventional) groups will apply not more than
three insulin injections per day without making allowance
for different meal sizes or flexible insulin dosage adap-
tions apart from ambient blood glucose.
Study population, inclusion and exclusion criteria
Subjects are recruited from diabetic patients diagnosed
with type-1 diabetes not more than three months ago.
Type-1 diabetes is defined by more than one elevated
blood glucose (concentration >11.1 mmol/l), and the
medical decision to prescribe insulin within three months
after diagnosis. The frequency of antibodies indicating an
autoimmune process is expected to be less than 50% in
adult type-1 diabetes [10,11]. Therefore the presence of
diabetes related antibodies may support diagnosis but
will be not mandatory for incusion.
Inclusion criteria
 Men or women aged 18–40 years at diagnosis
 Established Type-1 Diabetes diagnosed up to three
months ago
 Consent to participate in a diabetes training
programme
 Informed consent before enrollment
Exclusion criteria
 History of neuropathy, nephropathy, and retinopathy
of other than diabetes related origin
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 Negative C-peptide level at diagnosis
 History of psychiatric disease or drug or alc ohol abuse
 Treatment with oral antidiabetic medication
 Subject unlikely to comply with the protocol (e.g. ina-
bility or unwillingness to participate adequate training or
to complete diaries appropriately) or to understand the
nature and the scope of the study
Subsequent eligible patients and their status concerning
the study are recorded. Additionally, the number of those
patients refusing data collection are recorded in each
centre.
Compliance of patients after inclusion
A patient is considered non-compliant when he/she:
- misses more than two visits without contacting the study
centre
- moves and does not provide a new address or phone
number
- Wants to change therapy due to personal reasons
Primary endpoints and hypotheses
Our overall objectives formulated above made it neces-
sary to define two primary endpoints:
As we are interested in the preservation of C-peptide con-
centration under both therapies, one primary endpoint of
interest is the 'change of C-peptide concentration'
between baseline and three years follow-up (∆C-Peptide = C-
peptideprae - c-peptidepost). The other primary endpoint of
interest is 'failure'. of therapy. 'Failure' is a dichotomous
variable and defined as follows:
 The occurrence of an GHb value greater than 6,7 %
(upper 2-SD limit of central laboratory) twice in
succession.
 Decrease of fasting C-peptide to a value less or equal
0.15 nmol/l or stimulated C-peptide to a value less or
equal 0.3 nmol/l diagnosed twice in succession.
 The occurrence of albumine in collected urine, i. e. an
excretion rate greater than 21 µg/min once.
 The diagnosis of neuropathy or retinopathy, examined
in 1-year intervals.
'Failure' is stated if at least one of these items will occur.
The main question will be analysed in form of confirma-
tory hypothesis testing. H0 and H1, are defined for the two
primary endpoints as follows:
Primary endpoint 'change of C-peptide'
As the level of C-peptide under three years of therapy may
depend on baseline values, these must be taken into
account as one of the covariates in the analysis. The two
factors of interest are 'therapy' and the 'willingness of
patients to take part' in such a clinical study. According to
our question the interaction hypothesis is the one of
interest.
So the nullhypothesis is as follows:
H0: Under consideration of baseline data, the willingness
of patients has no influence on the difference of C-peptide
levels between patients under intensive therapy and con-
ventional therapy. That means there is no interaction
between both factors.
Against the alternative
H1: Under consideration of baseline data the difference of
C-peptide levels between patients under intensive therapy
and conventional therapy depends on the willingness of
the patients to take part in such a clinical study
Primary endpoint 'failure' of the therapy
H0: Intensive insulin therapy has a failure rate greater or
equal to the conventional therapy
P(failure | ICT) ≥ P(failure | CT)
H1: The failure rate of intensive therapy is less than the
rate of conventional therapy.
P(failure | ICT) < P(failure | CT)
Both hypotheses are formulated as a one-sided statistical
question.
Secondary endpoints and hypotheses
Apart from the main hypotheses we will investigate sev-
eral secondary questions in form of explorative data
analysis.
One point of interest is the effect of conventional vs.
intensive insulin therapy on the incidence of severe
hypoglycemia. In this regard we want to know the effect of
C-peptide at diagnosis on the incidence of severe hypogly-
cemia and on the trend of glycosylated hemoglobin
within three years of observation. Hypoglycemia will be
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retrieved according to the Working Group on Structured
Diabetes Therapy [7].
We will test the influence of the "change of C-peptide con-
centration" on the occurrence of diabetic complications at
the end of the observation time, such as the concentration
of albumin in urine. In case of a beneficial effect of C-pep-
tide, we will then evaluate the influence of body weight at
diagnosis as well as change of body weight under therapy
on the progress of C-peptide concentration.
Analysis of the primary endpoints
We are interested in the probability of 'failure' under the
different therapies. As 'failure' is a dichotomous variable,
the results of the study will be analysed by means of logis-
tic regression measures. The independent variable of inter-
est (exposure variable) is therapy with the two expressions
ICT and CT. As explained before, we have to take into
account, that the effect of therapy may be modified by the
patients' willingness to participate in a clinical study.
Therefore 'willingness' and the interaction term 'therapy *
willingness' is a part of the model. Variables observed at
baseline like GHb and C-peptide and scores describing
patient's psychical situation are confounders of the
model.
As we assume, that 'the change of C-peptide' depends on
the baseline values, the influence of the therapy will be
evaluated by analysis of covariance in consideration of
patients' agreement to take part in a clinical study. That
means the two factors of interest are 'therapy' and 'willing-
ness'. For our approach the interaction hypothesis is the
important one. As the assumption of the normal distribu-
tion of C-peptide is questionable for the analysis the non-
parametric analogue will be used.
Level of significance
As described we defined two primary endpoints in the
study protocol. It seems to be adequate to choose alpha =
0.05 as the familywise error rate. To take into account the
arising multiple comparison problem we perform the
Bonferroni-Procedure for the final evaluation of each pri-
mary variable in order to control the familywise error rate.
Analysis Set
The statistical analysis of the two primary endpoints will
be calculated based on the full analysis set to prevent from
an overoptimistic estimate. In order to take into account,
that drop outs (see definition non compliers) could falsify
the estimation of the primary endpoint 'failure' sensitivity
analysis will be done. For the second primary endpoint
'change of C-peptide' the method 'last observation carried
forward' will be used.
Patients who change their therapy will be analysed as ran-
domised. Furthermore, different frequencies of 'therapy
change' in the therapeutic cohorts must be taken into
account. It is expected that 'therapy change' will be rare in
the intensive group compared to the conventional group.
Under this assumption and the additional assumption
that the drop out rate in the intensive therapy group will
be lower than in the conventional group missing values
will be controlled for by carrying the last value forward.
This procedure will be applied to all non-compliant
patients, i.e. drop outs and therapy changers, regarding
the second primary endpoint 'change of C-peptide'. All
other variables defining one of the secondary endpoints
will be analysed in an explorative way.
Calculation of sample size
The study consists of a variable recruiting period and a
three-year follow-up. An eligible patient will be observed
three years at least. Because of the long-term observation,
we expect a constantly increasing number of drop outs
during follow-up caused by non-compliance. We estimate
an overall drop out rate of about 10 %. As mentioned
before two primary parameters, failure rate and change of
C-peptide-level, will be analysed. According to the results
of the pilot study we assume, that conventional therapy
causes a failure-rate of 0.3, that means P(failure 1 CT) =
0.3. From a clinical point of view it is desirable to reduce
this failure-rate to at least 0.15 in the intensive therapy in
contrast to the conventional therapy, that means P(failure
2 CT) = 0.15. With a type I error of α = 0.025 and a power
of 80 % we have to recruit at least 132 patients in each
therapeutic group.
From the clinical point of view it will also be desirable to
reduce 'the decline in the C-peptide-level', the second pri-
mary parameter, from the expected 0.75 nmol/l in the
conventional therapy to 0.5 nmol/l under intensive ther-
apy. In a pilot study we estimated a common standard
deviation of the C-peptide-level of 0.52. With a type I
error of α = 0.025 and a power of 80% in order to fulfil
conditions for these parameters we have to recruit 82
patients in each therapy group. With a 10% drop out rate
we have to recruit at least 91 patients for each group.
Because of a familywise evaluation of both primary end-
points the result of the primary parameter 'failure rate' was
taken as a basis, i. e. 132 patients per therapy arm have to
be recruited including the drop-out rate.
Randomisation procedure
The assignment to one of the therapy arms is made by the
study center at Giessen. Patients and diabetes profession-
als are both informed on the result of the randomisation.
From the medical point of view variables, which have to
be similarly distributed in the therapy arms are 'age of theBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/5
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patients', 'C-peptide' and 'body mass index' (BMI). As it is
expected that a single study center recruits a relatively
small number of patients, we randomise on the basis of a
'minimisation' procedure with defined variables. The pos-
sible values of the variables are divided into two intervals
according to the table 1:
Efficacy Data
Clinical Data
Overall examination of the patients will include all the
items of the St. Vincent Declaration data collection form
[12]. This includes foot examination with palpation of
pulses and screening sensation loss with the Rydel-Seiffer-
Tuning fork as described by Liniger et al [13]. A sensa-
tional loss of < 6/8 will be denominated „neuropathy".
Handling of the tuning fork and symptom questionnaire
are described by the Foot Working Group of the Deutsche
Diabetesgesellschaft http://www.ag-fuss-ddg.de.
Retinopathy is diagnosed by ophthalmologists according
to a standardized procedure [14] used previously in a pop-
ulation based study in the city of Wolfsburg, Germany on
more than 2,800 diabetic patients [15].
Central Laboratory Data
The main parameters are determined at the central study
laboratory of Giessen. Glycated hemoglobin is measured
by high-performance liquid chromatography at baseline
and every six months after inclusion into the study [16].
C-peptide is measured using a highly specific two-site
monoclonal antibody immunoradiometric assay and
blood glucose by the hexokinase method.
Concentration of urine albumine is not determined in a
centralized fashion. Therefore, a cross-validation proce-
dure was introduced. Frozen urine samples are sent to
each of the participant's laboratories once a year.
Between- and within-laboratory means, standard devia-
tions, and coefficients of variation are calculated as factors
of variability.
Data Quality Management
A relational database was developed to facilitate data
entry and control data quality. Predefined members of the
study group review the data base at various intervals
throughout the study. They assess completeness and
validity of data and safety aspects. They make sure that
queries generated by the data bank are responded and cor-
rections are entered into the data bank.
An important issue is coordinating the patient visits com-
ing from all over Germany. Not only have the patients to
be reminded of their visits but also the centres need to
know when each patient is due for a visit. Therefore, both,
centre and patient, have to be informed to ensure that the
patient admits to the centre. Therefore, a module com-
bined with the database was created to establish a mailing
system for the patient visits. This system
 calculates dates of the next visits for all patients,
 automatically prints a letter to all patients due for a visit
within one month's time
 prints a monthly reminder for the centres listing those
patients with visits due the next three months.
Another issue in every clinical study is the achievement of
optimal data quality with reasonable expense. We tried to
solve this problem by a high level of automation and a
flexible deployment of study-staff. Examples for these
automated processes are lists of patient schedules for all
participating centres sent at regular intervals, inventory of
visit-reminders for patients, randomisation of patients,
and basic data plausibility control.
Continuous safety and quality review (Source data 
verification)
Data safety and quality are monitored in predefined inter-
vals. Study report files are regularly sent to the study centre
where they are reviewed for inconsistent or missing data.
When data from the report files are entered into the data
base they are automatically checked for plausibility in
relation to the last data set of the same patient. Finally,
new data are balanced with the patient files at the occa-
sion of the monitoring visits. If one of these steps yields
missing or false data a query is prepared and sent back by
fax or mail to the individual center. Corrected data are
also sent back by mail or collected at the monitoring visit.
Table 1: Possible values for the defined variables used.
Variable C-peptide nmol/l age years BMI kg/m2
Interval 1 < 0.3 18 ≤ age < 30 < 21 kg/m2
Interval 2 ≥ 0.3 30 ≤ age ≤ 40 ≥ 21 kg/m2
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Centre performance
A periodical newsletter is sent to the centres containing
data on centre performance. This letter contains, for
instance, the following rates
- recruitment rate (number of recruited patients per year
compared to the estimated number of patients per year)
- time for incoming data and available source data com-
pared to required data).
- dropout rate (dropouts compared to the total patient
number per centre)
Elements of flexible staff management
An important element is the adaptation of study related
qualifications of the medical and biometrical team to
changing requirements in the course of the study. Since
the principal investigator is also responsible for patients
himself he will combine the study protocol with personal
medical practice and communicate his experiences to the
other investigators.
Visits
Another serious problem is the change of address in long-
term studies. Therefore, we developed a form for patients
planning to move in the next few months. The patient will
be asked to fill in their new address.
We have found out that minimal interference of study vis-
its with occupational or private life of the patients is a
major factor for adherence to arrangements made by phy-
sicians and diabetes educators with the patients. By defi-
nition age at inclusion is 18 to 40 years, i.e. most of the
patients are expected to be engaged in an occupation. This
is especially important for patients with diabetes related
problems at work.
We also arrange visits at weekends or in the evenings
when patients are not obliged to leave their working place
during the week. Patients are called by phone or cellular-
phone in the evening in case they have not made an
appointment up to four weeks following the automated
reminding letter was sent off. The medical staff is
informed about exceptional visit dates and will be present
when the patient enters the centre. Investigators are sup-
ported in organising the visits for a given patient.
Handling of Bias
Health care providers' preference
For the reasons described in the introduction health care
providers in Germany are expected to consider intensive
therapy to be optimal from the first day of diagnosis due
to the results of the DCCT trial. In addition, professionals
tend to have their own attitudes concerning the appropri-
ate therapy for a given patient [17], which may be differ-
ent from the patient' s attitude.
To harmonize therapeutic regimes we invited representa-
tives of the study centres to discuss details in which way
either intensive or conventional therapy was performed in
their own clinical setting. After meeting twice the thera-
peutic regimes were defined in the study protocol. At the
meetings the examiners were requested to inform their
patients such that no therapy was superior to the other at
diagnosis of diabetes even if they personally would prefer
the intensive therapy because of delay of complications
after many years of diabetes duration.
Patient Preference
Patients are responsible for their insulin therapy involving
individual social surroundings. Patients' success of treat-
ment and quality of glucose management is often related
to the attitude towards disease.
As the manifestation of the disease is a very profound
event for the patients, they might easily be influenced by
a lot of factors for example by the attitudes of their diabe-
tologists towards therapy, by other patients with diabetes
in a later stage of the disease, as well as the support offered
by family and friends. Very sensitive in this state of the dis-
ease, they might be guessing what therapy the health care
professional would prefer, even if he tries to be neutral.
Therefore we expect that not every patient of the possible
study population will agree to the restricting feature of an
experimental clinical study nor to the randomisation into
one of the two therapy regimes. On the contrary, we even
expect a selection bias. Further we assume, that especially
younger or self-confident diabetic patients would prefer a
more complicated regime in order to reach more freedom
concerning the flexibility of working hours and career
prospects, the selection of food and drinks, leisure time
activities and so on. So there is reason to doubt, that this
group would give their consent to take part in such a
study. Those patients are likely to insist on the intensive
insulin therapy possibly developing a more generous atti-
tude towards their disease not being anxious to fail in
handling the more complicated therapy regime.
On the other hand the first manifestation of diabetes
could make the patients insecure, the diagnosis of diabe-
tes sometimes causes psychical crisis. For such patients a
fixed therapy regime could be helpful. These and many
other facts can influence the patient' s consent to take part
in clinical trials and therefore cause a selection bias [18].
Zelen was the first who took into account bias caused by
patient' s preference or disagreement with randomisation
results [19]. The methods developed by him to handle
this bias cannot be chosen in our situation.BMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/5
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In this study there will be no comparison between a stand-
ard and an experimental therapy, but a comparison
between two common therapies, which appliances
depends on the patient' s and his caregiver' s preferences.
As mentioned before in addition both therapies have spe-
cific demands on the patient himself and his management
of his everyday life. Therefore we believe, that a lot of
patients will not consent to participation in such a clinical
trial.
Patient-related bias
Theoretically, to demonstrate the superiority of one of
both therapies the conduction of an observational study
alone would not be sufficient, since effects of 'therapy'
and 'patients' preferences' would be mixed. Therefore,
randomisation is essential. On the other hand, patients
who agree on randomised participation may not be repre-
sentative due to selection bias. In order to estimate such a
potential bias, the observational cohort was introduced
into the study. If different outcomes in the observational
and the controlled randomised cohort will result, we will
estimate the impact of the confounding factor 'patients'
preferences' and therewith control for a possible selection
bias. In a multifactorial analysis we look for interactions
of the two therapies and the factor 'consent: yes/no'. If we
do not find evidence of interaction we will search for a
global effect of the factor 'consent' alone.
By additionally introducing the observational study, we
actually analyse four subgroups: the randomised cohort
with the two therapies according to randomisation proce-
dure and the observational cohorts also consisting of the
two therapeutic groups, intensive or conventional ther-
apy, respectively.
Centre effects
In agreement with the centres we established a training
curriculum, so that patients are trained almost identically
concerning knowledge and didactic methods.
All eligible patients receive a basic diabetes training with
defined topics independent from the kind of therapy.
During this initial training patients are informed about
the study and asked to give their consent. To decrease cen-
tre-related effects a curriculum was developed for both
therapy arms synchronized in content, methods and time.
Basic training is followed by a more thorough training
programme according to the demands of the therapy. We
will also check the level of patients' knowledge treated in
the different centres and therapies. That is why we chose a
validated test (DWT Typ-1-Test) as control instrument to
measure the theoretical knowledge conveyed by diabetes
education [20-22].
There are more psychological factors influencing the out-
come of diabetes therapy, for example the patients' atti-
tude towards disease, his/her individual coping strategies,
or family support. Therefore, we will integrate a psycho-
logical assessment reflecting therapy contentment [23],
attitude of patients towards their disease, and how they
cope with the requirements of insulin therapy. The ques-
tionnaire consists of 45 diabetes-specific items evaluated
on nearly 2,000 individuals with type 1 or type 2 diabetes
including eight scales (values of Cronbach's alpha 0.69–
0.81) and a re-test reliability of 0.63 [24]. This question-
naire will be repeated every six months during the course
of the study. We expect to learn more about individual
motives for the confounding factor 'patient preferences'.
Development of standard operating procedures for 
patient training courses
Multicenter clinical trials on the effect of non-pharmaco-
logic intervention in diabetic patients are rare and often
lack standardized procedures. Even in the DCCT trial no
effort was undertaken to standardize patient education
between the centres. A reason for this situation is that the
implementation of evaluated curricula in an individual
training center depends on the specific local conditions,
such as adequate rooms, number of personel, qualifica-
tion of personel, cooperations with other medical facili-
ties, etc.
Training is undoubtedly one of the most important ele-
ments of therapy of newly diagnosed patients and there-
fore we organized two consensus conferences inviting
doctors and diabetes educators of the participating centres
to find a common guideline concerning patient training.
This guideline was added to the treatment protocol as an
amendment.
In short, every patient is instructed how to inject mixed
insulin preparations and how to monitor blood glucose
in the first week after diagnosis. After randomisation a
training course with 20 lessons of 45 min each will be
offered for each patient. Education goals and methods
were defined by the study consensus meetings in accord-
ance with the guidelines of the German and European
Diabetes Societies [21]. Only registered diabetes educa-
tors are allowed to train the study patients.
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